Anti-OR10V1 (Aa 280-309) Polyclonal Antibody (DPABH-21566) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page:16

File Type:pdf, Size:1020Kb

Anti-OR10V1 (Aa 280-309) Polyclonal Antibody (DPABH-21566) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use Anti-OR10V1 (aa 280-309) polyclonal antibody (DPABH-21566) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms. Immunogen Synthetic peptide conjugated to KLH, corresponding to a region within C terminal amino acids 280-309 of Human OR10V1 (NP_001005324.1). Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB Format Liquid Size 400 μl Buffer Constituent: 99% PBS Preservative 0.09% Sodium Azide Storage Store at 4°C (up to 6 months). For long term storage store at -20°C GENE INFORMATION 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Gene Name OR10V1 olfactory receptor, family 10, subfamily V, member 2 [ Homo sapiens ] Official Symbol OR10V1 Synonyms OR10V1; olfactory receptor, family 10, subfamily V, member 1; OR11-256; olfactory receptor 10V1; olfactory receptor OR11-256; Entrez Gene ID 390201 Protein Refseq NP_001005324.1 UniProt ID Q8NGI7 Pathway GPCR downstream signaling; Olfactory transduction; Signal Transduction. Function G-protein coupled receptor activity; olfactory receptor activity; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
Recommended publications
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • Chr CNV Start CNV Stop Gene Gene Feature 1 37261312 37269719
    chr CNV start CNV stop Gene Gene feature 1 37261312 37269719 Tmem131 closest upstream gene 1 37261312 37269719 Cnga3 closest downstream gene 1 41160869 41180390 Tmem182 closest upstream gene 1 41160869 41180390 2610017I09Rik closest downstream gene 1 66835123 66839616 1110028C15Rik in region 2 88714200 88719211 Olfr1206 closest upstream gene 2 88714200 88719211 Olfr1208 closest downstream gene 2 154840037 154846228 a in region 3 30065831 30417157 Mecom closest upstream gene 3 30065831 30417157 Arpm1 closest downstream gene 3 35476875 35495913 Sox2ot closest upstream gene 3 35476875 35495913 Atp11b closest downstream gene 3 39563408 39598697 Fat4 closest upstream gene 3 39563408 39598697 Intu closest downstream gene 3 94246481 94410611 Celf3 in region 3 94246481 94410611 Mrpl9 in region 3 94246481 94410611 Riiad1 in region 3 94246481 94410611 Snx27 in region 3 104311901 104319916 Lrig2 in region 3 144613709 144619149 Clca6 in region 3 144613709 144619149 Clca6 in region 4 108673 137301 Vmn1r2 closest downstream gene 4 3353037 5882883 6330407A03Rik in region 4 3353037 5882883 Chchd7 in region 4 3353037 5882883 Fam110b in region 4 3353037 5882883 Impad1 in region 4 3353037 5882883 Lyn in region 4 3353037 5882883 Mos in region 4 3353037 5882883 Penk in region 4 3353037 5882883 Plag1 in region 4 3353037 5882883 Rps20 in region 4 3353037 5882883 Sdr16c5 in region 4 3353037 5882883 Sdr16c6 in region 4 3353037 5882883 Tgs1 in region 4 3353037 5882883 Tmem68 in region 4 5919294 6304249 Cyp7a1 in region 4 5919294 6304249 Sdcbp in region 4 5919294
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • Explorations in Olfactory Receptor Structure and Function by Jianghai
    Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 ABSTRACT Explorations in Olfactory Receptor Structure and Function by Jianghai Ho Department of Neurobiology Duke University Date:_______________________ Approved: ___________________________ Hiroaki Matsunami, Supervisor ___________________________ Jorg Grandl, Chair ___________________________ Marc Caron ___________________________ Sid Simon ___________________________ [Committee Member Name] An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Neurobiology in the Graduate School of Duke University 2014 Copyright by Jianghai Ho 2014 Abstract Olfaction is one of the most primitive of our senses, and the olfactory receptors that mediate this very important chemical sense comprise the largest family of genes in the mammalian genome. It is therefore surprising that we understand so little of how olfactory receptors work. In particular we have a poor idea of what chemicals are detected by most of the olfactory receptors in the genome, and for those receptors which we have paired with ligands, we know relatively little about how the structure of these ligands can either activate or inhibit the activation of these receptors. Furthermore the large repertoire of olfactory receptors, which belong to the G protein coupled receptor (GPCR) superfamily, can serve as a model to contribute to our broader understanding of GPCR-ligand binding, especially since GPCRs are important pharmaceutical targets.
    [Show full text]
  • Download from the Sequence Read Archive Repository ( 421 Under the Accession Number SRP070526
    bioRxiv preprint doi: https://doi.org/10.1101/058446; this version posted June 12, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Article 2 Discoveries 3 4 Title 5 Deciphering the wisent demographic and adaptive histories from individual 6 whole-genome sequences 7 8 Authors and Affiliations 9 Mathieu GAUTIER1,2§, Katayoun MOAZAMI-GOUDARZI3, Hubert LEVEZIEL4, Hugues 10 PARINELLO5, Cécile GROHS3, Stéphanie RIALLE5, Rafał KOWALCZYK6, Laurence 11 FLORI3,7§ 12 1 CBGP, INRA, CIRAD, IRD, Supagro, 34988 Montferrier-sur-Lez, France 13 2 IBC, Institut de Biologie Computationnelle, 34095 Montpellier, France 14 3 GABI, INRA, AgroParisTech, Université Paris-Saclay, 78350 Jouy-en-Josas, France 15 4 UGMA, INRA, Université de Limoges, 87060 Limoges, France 16 5 MGX-Montpellier GenomiX, c/o Institut de Génomique Fonctionnelle, Montpellier, France 17 6 Mammal Research Institute, Polish Academy of Sciences, 17-230 Białowieża, Poland 18 7 INTERTRYP, CIRAD, IRD, 34398 Montpellier, France 19 20 §Corresponding authors 21 Emails: 22 [email protected] 23 [email protected] 24 1 bioRxiv preprint doi: https://doi.org/10.1101/058446; this version posted June 12, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 25 Abstract 26 As the largest European herbivore, the wisent (Bison bonasus) is emblematic of the continent 27 wildlife but has unclear origins. Here, we infer its demographic and adaptive histories from 28 two individual whole genome sequences via a detailed comparative analysis with bovine 29 genomes.
    [Show full text]
  • {'Ess': 0, 'Noness': 3} True 70007 AAGATCTAAAACTTTACACTAG []
    uag2uaa_1_13_window gene gene_ogee gene_essentiality site_index cbe_targets abe_targets 0 1 OR4F5 {'ess': 0, 'noness': 3} True 70007 AAGATCTAAAACTTTACACTAG [] 1 1 PERM1 unavailable False 976171 TGGCTCCTAGGAGCTGGGGCTG [] 2 1 RNF223 unavailable False 1071816 TGGCCCTAATTATCAGTCAGAG [] 3 1 TTLL10 {'ess': 0, 'noness': 7} True 1185524 CCTTAGCTAGGGAGAGTCCGGG [] 4 1 TTLL10 {'ess': 0, 'noness': 7} True 1197846 TGGCTGCCCCTAGGGCCTCGCG[] 5 1 TNFRSF18 {'ess': 0, 'noness': 7} True 1203590 TCCTAAGACCCCACCCCATCAG [] 6 1 ACAP3 {'ess': 0, 'noness': 7} True 1293563 CCGGCCCTAGCTCTCTTCCAGG [] 7 1 CPTP unavailable False 1327762 CCCGCCCCTAGGGCAGGTCCAG[] 8 1 MXRA8 {'ess': 0, 'noness': 7} True 1353603 CCTATTTGCAGTTCTCCTTCCG [] 9 1 MRPL20 {'ess': 6, 'noness': 2} False 1402568 TGGCCTAGGGTAACCCTTTAAG [] 10 1 ATAD3B {'ess': 0, 'noness': 7} True 1495816 CCAGTGCCTACAACAGGGGGTG [] 11 1 MMP23B {'ess': 0, 'noness': 7} True 1634328 TCACTACACTTTCCCTTTCTTG [] 12 1 NADK {'ess': 4, 'noness': 5} False 1752903 -1 -1 13 1 CALML6 {'ess': 1, 'noness': 7} True 1917192 CTGCACCTACTGGATCAGCTTG [] 14 1 PRKCZ {'ess': 1, 'noness': 7} True 2157294 GGGACGCCCTAGTAGCTGGCTG [] 15 1 SKI {'ess': 2, 'noness': 6} False 2306764 GGAATCTACGGCTCCAGCTCCG [] 16 1 MORN1 {'ess': 0, 'noness': 7} True 2355447 CGTCTGATCCTAGAAGAGTGAG [] 17 1 RER1 {'ess': 1, 'noness': 5} False 2403123 TCCCGCTTCTAGCTGGCGAAGG [] 18 1 PRXL2B unavailable False 2589478 AGCACACCTAGGGCAGCAGACG [] 19 1 MMEL1 {'ess': 1, 'noness': 7} True 2590989 TTGGCTACCACACGCGGCATCG [] 20 1 ARHGEF16 {'ess': 0, 'noness': 7} True 3480586 GCTACACGTCCGTCTCCACCCG
    [Show full text]
  • Online Supporting Information S2: Proteins in Each Negative Pathway
    Online Supporting Information S2: Proteins in each negative pathway Index Proteins ADO,ACTA1,DEGS2,EPHA3,EPHB4,EPHX2,EPOR,EREG,FTH1,GAD1,HTR6, IGF1R,KIR2DL4,NCR3,NME7,NOTCH1,OR10S1,OR2T33,OR56B4,OR7A10, Negative_1 OR8G1,PDGFC,PLCZ1,PROC,PRPS2,PTAFR,SGPP2,STMN1,VDAC3,ATP6V0 A1,MAPKAPK2 DCC,IDS,VTN,ACTN2,AKR1B10,CACNA1A,CHIA,DAAM2,FUT5,GCLM,GNAZ Negative_2 ,ITPA,NEU4,NTF3,OR10A3,PAPSS1,PARD3,PLOD1,RGS3,SCLY,SHC1,TN FRSF4,TP53 Negative_3 DAO,CACNA1D,HMGCS2,LAMB4,OR56A3,PRKCQ,SLC25A5 IL5,LHB,PGD,ADCY3,ALDH1A3,ATP13A2,BUB3,CD244,CYFIP2,EPHX2,F CER1G,FGD1,FGF4,FZD9,HSD17B7,IL6R,ITGAV,LEFTY1,LIPG,MAN1C1, Negative_4 MPDZ,PGM1,PGM3,PIGM,PLD1,PPP3CC,TBXAS1,TKTL2,TPH2,YWHAQ,PPP 1R12A HK2,MOS,TKT,TNN,B3GALT4,B3GAT3,CASP7,CDH1,CYFIP1,EFNA5,EXTL 1,FCGR3B,FGF20,GSTA5,GUK1,HSD3B7,ITGB4,MCM6,MYH3,NOD1,OR10H Negative_5 1,OR1C1,OR1E1,OR4C11,OR56A3,PPA1,PRKAA1,PRKAB2,RDH5,SLC27A1 ,SLC2A4,SMPD2,STK36,THBS1,SERPINC1 TNR,ATP5A1,CNGB1,CX3CL1,DEGS1,DNMT3B,EFNB2,FMO2,GUCY1B3,JAG Negative_6 2,LARS2,NUMB,PCCB,PGAM1,PLA2G1B,PLOD2,PRDX6,PRPS1,RFXANK FER,MVD,PAH,ACTC1,ADCY4,ADCY8,CBR3,CLDN16,CPT1A,DDOST,DDX56 ,DKK1,EFNB1,EPHA8,FCGR3A,GLS2,GSTM1,GZMB,HADHA,IL13RA2,KIR2 Negative_7 DS4,KLRK1,LAMB4,LGMN,MAGI1,NUDT2,OR13A1,OR1I1,OR4D11,OR4X2, OR6K2,OR8B4,OXCT1,PIK3R4,PPM1A,PRKAG3,SELP,SPHK2,SUCLG1,TAS 1R2,TAS1R3,THY1,TUBA1C,ZIC2,AASDHPPT,SERPIND1 MTR,ACAT2,ADCY2,ATP5D,BMPR1A,CACNA1E,CD38,CYP2A7,DDIT4,EXTL Negative_8 1,FCER1G,FGD3,FZD5,ITGAM,MAPK8,NR4A1,OR10V1,OR4F17,OR52D1,O R8J3,PLD1,PPA1,PSEN2,SKP1,TACR3,VNN1,CTNNBIP1 APAF1,APOA1,CARD11,CCDC6,CSF3R,CYP4F2,DAPK1,FLOT1,GSTM1,IL2
    [Show full text]
  • Supplemental Table S18. Cellular Process Enrichment Analysis Output
    Supplemental Table S18.
    [Show full text]
  • Impact of Non-Thermal Plasma on Cell Signaling in Keratinocytes
    Impact of non-thermal plasma on cell signaling in keratinocytes Inauguraldissertation zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Ernst-Moritz-Arndt-Universität Greifswald vorgelegt von Annemarie Barton geboren am 12.04.1986 in Bielefeld Greifswald, Dezember 2013 Dekan: Prof. Dr. Klaus Fesser 1. Gutachter: Prof. Dr. Ulrike Lindequist 2. Gutachter: Prof. Dr. David Graves Datum der Verteidigung: 24.04.2014 Contents 1 Introduction 5 1.1 Plasma . .5 1.2 Human Skin . .7 1.3 Wound Healing . .8 1.3.1 Acute wound . .8 1.3.2 Chronic wound . 11 1.4 Plasma medicine . 13 1.5 Aim of the work . 14 2 Materials and Methods 15 2.1 Materials . 15 2.1.1 Chemicals and solutions . 15 2.1.2 General laboratory equipment . 16 2.1.3 Kits . 16 2.1.4 Instruments . 17 2.1.5 Software . 18 2.1.6 Buffers and solutions . 19 2.2 Methods . 19 2.2.1 Cell culture . 19 2.2.2 Plasma source . 20 2.2.3 Plasma treatment . 22 2.2.4 Preparation of conditioned medium . 23 2.2.5 Co-culture with keratinocytes and monocytes . 24 2.2.6 Cell survival . 25 2.2.7 Gene expression analysis . 26 2.2.8 Protein expression analysis . 32 3 Results 34 3.1 Impact of plasma on HaCaT cells . 34 3.1.1 Cell survival . 34 3.1.2 Transcription profile . 36 3.1.3 Secretion profile . 44 3.2 Impact of the shielding gas . 48 3.2.1 Cell survival .
    [Show full text]
  • Identifying Drug Sensitivity Subnetworks with NETPHIX
    bioRxiv preprint doi: https://doi.org/10.1101/543876. this version posted February 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license. Identifying Drug Sensitivity Subnetworks with NETPHLIX Yoo-Ah Kim *† Rebecca Sarto Basso *†‡ Damian Wojtowicz † Dorit S. Hochbaum ‡ Fabio Vandin §¶ Teresa M. Prztycka †¶ Abstract Phenotypic heterogeneity in cancer is often caused by different patterns of genetic alterations. Under- standing such phenotype-genotype relationships is fundamental for the advance of personalized medicine. One of the important challenges in the area is to predict drug response on a personalized level. The pathway- centric view of cancer significantly advanced the understanding of genotype-phenotype relationships. How- ever, most of network identification methods in cancer focus on identifying subnetworks that include gen- eral cancer drivers or are associated with discrete features such as cancer subtypes, hence cannot be applied directly for the analysis of continuous features like drug response. On the other hand, existing genome wide association approaches do not fully utilize the complex proprieties of cancer mutational landscape. To ad- dress these challenges, we propose a computational method, named NETPHLIX (NETwork-to-PHenotpe mapping LeveragIng eXlusivity), which aims to identify mutated subnetworks that are associated with drug response (or any continuous cancer phenotype). Utilizing properties such as mutual exclusivity and interac- tions among genes, we formulate the problem as an integer linear program and solve it optimally to obtain a set of genes satisfying the constraints. NETPHLIX identified gene modules significantly associated with many drugs, including interesting response modules to MEK1/2 inhibitors in both directions (increased and decreased sensitivity to the drug) that the previous method, which does not utilize network informa- tion, failed to identify.
    [Show full text]
  • Research/0018.1
    http://genomebiology.com/2001/2/6/research/0018.1 Research The human olfactory receptor repertoire comment Sergey Zozulya, ernando Echeverri and Trieu Nguyen Address: Senomyx Inc., 11099 North Torrey Pines Road, La Jolla, CA 92037, USA. Correspondence: Sergey Zozulya. E-mail: [email protected] reviews Published: 1 June 2001 Received: 8 March 2001 Revised: 12 April 2001 Genome Biology 2001, 2(6):research0018.1–0018.12 Accepted: 18 April 2001 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2001/2/6/research/0018 © 2001 Zozulya et al., licensee BioMed Central Ltd (Print ISSN 1465-6906; Online ISSN 1465-6914) reports Abstract Background: The mammalian olfactory apparatus is able to recognize and distinguish thousands of structurally diverse volatile chemicals. This chemosensory function is mediated by a very large family of seven-transmembrane olfactory (odorant) receptors encoded by approximately 1,000 genes, the majority of which are believed to be pseudogenes in humans. deposited research Results: The strategy of our sequence database mining for full-length, functional candidate odorant receptor genes was based on the high overall sequence similarity and presence of a number of conserved sequence motifs in all known mammalian odorant receptors as well as the absence of introns in their coding sequences. We report here the identification and physical cloning of 347 putative human full-length odorant receptor genes. Comparative sequence analysis of the predicted gene products allowed us to identify and define a number of consensus sequence motifs and structural features of this vast family of receptors.
    [Show full text]